SLC5A2 and type 2 diabetes mellitus: Evidence for SGLT-2 inhibitors: A systematic review and meta-analysis by Wang et al. [108] (18 studies, n=1063) in individuals with T2D reported that SGLT-2 inhibitors reduced visceral adipose tissue (SMD=−1.42, 95% CI (−2.02, −0.82), p < 0.0001), body weight (MD=−2.60, 95% CI (−3.30, −1.89), p < 0.0001), waist circumference (MD=−3.65, 95% CI (−4.10, −3.21), p < 0.0001), and BMI (MD=−0.81, 95% CI (−0.91, −0.71), p < 0.0001).